Novartis announced data that show majority of patients with polycythemia vera treated with Jakavi achieved long-term disease control.
The company said that preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi (ruxolitinib) experienced a durable response for at least one year[1]
According to the company, in the study, 83% of patients in the Jakavi arm remained on treatment; findings reinforce the long-term safety profile of Jakavi.
Furthermore, Jakavi, the only targeted therapy approved for PV in the EU, addresses an unmet need as 1 in 4 patients with PV is resistant to/intolerant of current treatments.